Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes.
Intravenous plasminogen therapy shows sustained benefit for children with a rare eye and throat disease, with optimized dosing guidance emerging.
IV plasminogen concentrate demonstrated sustained therapeutic efficacy in pediatric Type 1 plasminogen deficiency (an ultra-rare disorder causing ligneous conjunctivitis and mucosal pseudomembrane disease), with dosing parameter analysis providing guidance for optimizing treatment protocols in this small patient population. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective longitudinal clinical analysis (multi-site pediatric rare disease)
- Category
- rare_diseases
- Maturity
- Validated
- Journal
- Pediatr Blood Cancer
Why it surfaced
Type 1 plasminogen deficiency has extremely high unmet need with a very small patient population. Long-term dosing data from multiple centers is the maximum achievable evidence level for this disease. The findings have direct implications for treatment protocols globally and regulatory use.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.